Instituto Portugues de Oncologia do Porto, Francisco Gentil

Porto 4200-072

0 studies enrolling now · 6 studies all time

What they study most

Breast Cancer, Breast Tumor, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer, GVHD, HER2- Negative Breast Cancer, Hematopoietic Stem Cells, Lymphoma, Non-Hodgkin, Metastatic Breast Cancer, Multiple Myeloma, Progesterone Receptor- Negative Breast Cancer, Recurrent Breast Cancer

Studies at this site

• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy — Running, not enrolling
• Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) — Stopped early
• Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma — Completed
• Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation — Completed
• Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) — Completed
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) — Completed